Cannabinoid Control of Motor Function at the Basal Ganglia 507Szabo B, Dorner L, Pfreundtner C, Norenberg W, Starke K (1998) Inhibition of GABAergic
inhibitory postsynaptic currents by cannabinoids in rat corpus striatum. Neuroscience
85:395–403
Szabo B, Muller T, Koch H (1999) Effects of cannabinoids on dopamine release in the corpus
striatum and the nucleus accumbens in vitro. J Neurochem 73:1084–1089
Szabo B, Wallmichrath I, Mathonia P, Pfreundtner C (2000) Cannabinoids inhibit excitatory
neurotransmission in the substantia nigra pars reticulata. Neuroscience 97:89–97
Tersigni TJ, Rosenberg HC (1996) Local pressure application of cannabinoid agonists in-
creases spontaneous activity of rat substantia nigra pars reticulata neurons without
affecting response to iontophoretically-applied GABA. Brain Res 733:184–192
Tsou K, Brown S, Sañudo-Peña MC, Mackie K, Walker JM (1998a) Immunohistochemical
distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuro-
science 83:393–411
Tsou K, Nogueron MI, Muthian S, Sañudo-Peña M, Hillard CJ, Deutsch DG, Walker JM
(1998b) Fatty acid amide hydrolase is located preferentially in large neurons in the rat
central nervous system as revealed by immunohistochemistry. Neurosci Lett 254:137–
140
van der Stelt M, Di Marzo V (2003) The endocannabinoid system in the basal ganglia and in
the mesolimbic reward system: implications for neurological and psychiatric disorders.
Eur J Pharmacol 480:133–150
Westlake TM, Howlett AC, Bonner TI, Matsuda LA, Herkenham M (1994) Cannabinoid
receptor binding and messenger RNA expression in human brain: an in vitro receptor
autoradiography and in situ hybridization histochemistry study of normal aged and
Alzheimer’s brains. Neuroscience 63:637–652
Wickens AP, Pertwee RG (1993)∆9-Tetrahydrocannabinol and anandamide enhance the
ability of muscimol to induce catalepsy in the globus pallidus of rats. Eur J Pharmacol
250:205–208
Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, Thompson A (2003) Cannabinoids
for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS
study): multicentre randomised placebo-controlled trial. Lancet 362:1517–1526
Zaretsky A, Rector NA, Seeman MV, Fornazzari X (1993) Current cannabis use and tardive
dyskinesia. Schizophr Res 11:3–8
Zeng BY, Dass B, Owen A, Rose S, Cannizzaro C, Tel BC, Jenner P (1999) Chronic L-
DOPA treatment increases striatal cannabinoid CB1 receptor mRNA expression in 6-
hydroxydopamine-lesioned rats. Neurosci Lett 276:71–74
Zimmer A, Zimmer AM, Hohmann AG, Herkenham M, Bonner TI (1999) Increased mor-
tality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc
Natl Acad Sci USA 96:5780–5785
Zygmunt PM, Chuang H, Movahed P, Julius D, Hogestatt ED (2000) The anandamide trans-
port inhibitor AM404 activates vanilloid receptors. Eur J Pharmacol 396:39–42